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Live attenuated measles virus (MV) has long been recognized as a safe and effective
vaccine, and it has served as the basis for development of various MV-based vaccines.
However, because MV is a human-tropic virus, the evaluation of MV-based vaccines has
been hampered by the lack of a small-animal model. The humanized mouse, a recently
developed system in which an immunodeﬁcient mouse is transplanted with human fetal
tissues or hematopoietic stem cells, may represent a suitable model. Here, we developed
a sensitive one-step quantitative reverse transcription (qRT)-PCR that simultaneously
measures nucleocapsid (N) and human RNase P mRNA levels. The results can be used
to monitor MV infection in a humanized mouse model. Using this method, we elucidated
the replication kinetics of MV expressing enhanced green ﬂuorescent protein both in vitro
and in humanized mice in parallel with ﬂow-cytometric analysis. Because our qRT-PCR
system was sensitive enough to detect MV expression using RNA extracted from a small
number of cells, it can be used to monitor MV infection in humanized mice by sequential
blood sampling.
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INTRODUCTION
Measles, a highly contagious childhood disease caused by
the measles virus (MV), affects more than 20 million peo-
ple each year. MV infection is characterized by a high fever
with typical Koplik’s spots followed by the appearance of a
generalized maculopapular rash, and is often associated with
respiratory and neuronal complications (Grifﬁn, 2007). Since
the implementation of vaccination programs using an effec-
tive live attenuated MV vaccine, global measles deaths have
decreased dramatically. Nevertheless, measles is still one of the
leading causes of death among young children under the age
of 5 years, especially in countries with weak health infras-
tructures, and approximately 158,000 measles death occurred
in 2011 (http://www.who.int/mediacentre/factsheets/fs286/en/).
The ongoing global vaccination strategy aims to protect small
children at high risk.
The MV vaccine is safe, effective, and inexpensive. Based on its
long and successful vaccination history, several groups have taken
advantage of reverse-genetics technology to utilize the live attenu-
atedMV vaccine strain as a viral vector to elicit immune responses
against foreign antigens from various pathogens, such as Env or
Gag of human immunodeﬁciency virus (HIV; Lorin et al., 2004;
Stebbings et al., 2012), hepatitis B surface (S) antigen (Singh et al.,
1999; Reyes-del Valle et al., 2009), fusion protein of respiratory
syncytial virus (Sawada et al., 2011), and envelope glycoprotein of
West Nile virus (Despres et al., 2005; Brandler et al., 2012). MV
is a human-tropic virus that uses CD46, signaling of lymphocyte
activation molecule (SLAM, CD150), and the recently identiﬁed
epithelial-cell receptor nectin-4 (PVRL4, see review in Kato et al.,
2012) as receptors. To test the immune response againstMV-based
recombinant vaccines, both MV receptor-transgenic mice (Singh
et al., 1999; Lorin et al., 2004; Despres et al., 2005) and non-human
primates have been used as animal models (Reyes-del Valle et al.,
2009; Brandler et al., 2012; Stebbings et al., 2012).
Although non-human primates are susceptible to MV, and
they develop pathologies similar to those that occur in humans,
the expense of using monkeys in research limits the number of
animals that can be used for studies. To overcome such practi-
cal problems, various types of human MV receptor-transgenic
mice expressing CD46 or CD150 have been developed (review in
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Sellin and Horvat, 2009). Unfortunately, MV infection of all of
these human MV receptor-expressing mouse models is severely
restricted by the presence of murine type I IFN; to establish MV
infection, it is necessary to introduce the IFNα receptor knockout
into the MV receptor-transgenic mice, even in strains express-
ing CD150 driven by a native human promoter (Ohno et al.,
2007). The IFNα receptor knockout/CD150 knock-in mouse is
highly susceptible to MV infection and reproduces some aspects
of MV infection in humans, including immunosuppression (Koga
et al., 2010). This makes it a useful mouse model for study pur-
poses. However, one problem is the lack of an initial innate
immune response, which may modify the outcome of MV infec-
tion. Thus, the model may not truly reﬂect the outcome in
humans.
In the early 2000s, a series of immunodeﬁcient mice were
developed that allow efﬁcient transplantation of human cells or
tissues; these systems are collectively termed “humanized mice.”
A large number of studies have described the development of
human hematopoietic cells and their immunological functions
in humanized mice, and technical modiﬁcations have been made
for the study of various human diseases (Ito et al., 2012). Cur-
rently, humanized mouse systems are widely used as alternatives
to non-human primatemodels, especially for the study of human-
tropic infectious diseases such asHIV,humanT cell leukemia virus
(HTLV), dengue virus, HCV, and EB virus (Akkina, 2013). Of the
different humanized mice models, the BM/Liver/Thymus trans-
planted (BLT)mouse, which is transplanted with human fetal liver
and thymus tissue in addition to hematopoietic stem cells (HSCs),
is recognized as the model that most closely mimics the human
immune response (Wege et al., 2008). However, the use of this
model is limited, mainly because of the ethical issues surrounding
human fetal organs/tissues.
We have recently established an HIV infection model in
NOD/SCID/Jak3null (NOJ) mouse transplanted with human
cord blood HSCs (Terahara et al., 2013). To study MV infec-
tion in humanized NOJ (hNOJ), we infected an MV vaccine
strain (AIK-C) expressing enhanced green ﬂuorescent protein
(EGFP) into hNOJ and analyzed the MV-infected cells by ﬂow
cytometry. The hNOJ mouse is highly susceptible to MV infec-
tion; in that study, we observed that GFP+ cells were present
in systemic lymphoid tissues and bone marrow (BM). Because
it is important to assess MV infection kinetics in an animal
without sacriﬁcing the infected mouse, we developed a highly
sensitive one-step quantitative reverse transcription-PCR (qRT-
PCR) system to monitor MV infection in human peripheral
blood mononuclear cells (PBMCs) circulating in the blood of
humanized mice. In this study, we describe how this monitor-
ing systemworks and demonstrate that the results obtained reﬂect
the actual frequency of MV-infected cells, as determined by ﬂow
cytometry.
MATERIALS AND METHODS
CELL FRACTIONATION OF PBMCs
Peripheral blood mononuclear cells were obtained from human
blood samples of healthy volunteers. Samples were collected
after obtaining the approval of the institutional ethical commit-
tee of the National Institute of Infectious Diseases (NIID; No.
350) and written informed consent from each subject. PBMCs
were separated by Ficoll–Hypaque density-gradient centrifugation
(Lymphosepal; IBL, Gunma, Japan).
To obtain monocyte-derived dendritic cells (MDDCs), mono-
cytes were enriched from PBMCs using CD14 microbeads (Mil-
tenyi Biotec) and cultured in RPMI 1640 supplemented with 10%
fetal bovine serum (FBS), 2 mM glutamine, and antibiotics in
the presence of interleukin-4 (IL-4) and granulocyte–macrophage
colony-stimulating factor (GM-CSF; both 10 ng/ml, from Pepro-
Tech Inc., London, UK) for 1 week. T cells were isolated from
CD14-negative PBMCs using the Total T Cell Enrichment Kit
(STEMCELL technologies, Vancouver, BC, Canada).
PREPARATION OF RNA
Total RNA was extracted from mouse blood, BM, and spleen
of humanized mice, human PBMCs, and Jurkat cells expressing
human SLAM (Jurkat/hSLAM) using the RNeasy Mini Kit (QIA-
GEN, Valencia, CA, USA) or the Total RNA Isolation Mini Kit
(Agilent Technologies, Santa Clara, CA, USA).
To prepare a standard of MVRNA, the cDNA encodingmeasles
virus nucleocapsid (N) (MV-N: AB052821) was subcloned into
the pBluescript II vector, and then MV-N RNA was produced
by in vitro RNA transcription using the T7 RiboMAXTM Express
Large Scale RNA Production System (Promega, Madison, WI,
USA). The RNA product was puriﬁed by DNase treatment, fol-
lowedbyphenol–chloroformextraction and ethanol precipitation,
according to the protocol supplied by the manufacturer. The
ﬁnal concentration of RNA was measured using an ND-1000
spectrophotometer (Thermo,Waltham, MA, USA).
PREPARATION OF STANDARD TEMPLATE DNA
To prepare a standard template DNA, cDNAs of human CD45
(hCD45: NG_007730) and RNase P (NM_006413) were syn-
thesized from total RNA of CEM cells by reverse transcription
(RT)-PCR using SuperScript III RT/Platinum Taq Mix (Invitro-
gen, Carlsbad, CA, USA). The products were further ampliﬁed
by PCR using TaKaRa Ex Taq Hot Start Version (TAKARA, Otsu,
Shiga, Japan) for hCD45, or AmpliTaq Gold 360 (Applied Biosys-
tems, Carlsbad, CA, USA) for RNase P. These PCR products of
hCD45 and RNase P were subcloned into plasmids using the
pGeneBLAzer TOPOTAExpression kit (Invitrogen) and pGEM-T
(Easy) Vector Systems (Promega), respectively.
REAL-TIME RT-PCR ASSAY
To perform real-time qRT-PCR, SuperScript III Platinum One-
StepQuantitative RT-PCR system (Invitrogen)was used according
to themanufacturer’s instructions. Brieﬂy, each reaction contained
1× reaction mix, ROX reference dye, SuperScript III RT/Platinum
TaqMix, 0.2 μM speciﬁc primers, and 0.1 μM TaqMan probe.
Reactions were performed on an Mx3000P qPCR system (Agilent
Technologies). Thermocycling parameters included a RT step at
50◦C for 20 min, followed by a DNA polymerase activation step
at 95◦C for 2 min and 50 PCR cycles (95◦C for 20 s, 60◦C for
30 s). Threshold cycle (Ct) valueswere calculated for each reaction;
Ct represents the cycle at which a statistically signiﬁcant increase
in the emission intensity of the reporter relative to the passive
reference dye is ﬁrst detected.
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For detection of hCD45 mRNA, the following sequences were
used: forward primer, 5′-GGA AGT GCT GCA ATG TGT CAT
T-3′; reverse primer; 5′-CTT GAC ATG CAT ACT ATT ATC
TGA TGT CA-3′; TaqMan probe; 5′-FAM-ACA ACT AAA AGT
GCT CCT CCA AGC CAG GTC T-BHQ1-3′ (Hamaia et al.,
2001). For detection of RNase P mRNA: forward primer, 5′-
AGA TTT GGA CCT GCG AGC G-3′; reverse primer, 5′-GAG
CGG CTG TCT CCA CAA GT-3′; TaqMan probe, 5′-FAM-TTC
TGA CCT GAA GGC TCT GCG CG-BHQ1-3′ (Kimberly et al.,
2005). For detection of MV-N RNA: forward primer, 5′-CGA
TGA CCC TGA CGT TAG CA-3′; reverse primer, 5′-GCG AAG
GTA AGG CCA GAT TG-3′; TaqMan probe, 5′-FAM-AGG CTG
TTA GAG GTT GTC CAG AGT GAC CAG-BHQ1-3′ (Hummel
et al., 2006).
GENERATION OF HUMANIZED MICE
Humanized NOD/SCID/JAK3null mice were established as
described previously (Terahara et al., 2013). In brief, NOJ mice
were transplanted with human HSCs (0.5–1 × 105 cells) enriched
from human umbilical cord blood cells into the livers of irradi-
ated (1 Gy) newborn mice within 2 days after birth. All mice were
maintained under speciﬁc pathogen-free conditions in the animal
facility at NIID and were treated in accordance with the guide-
lines issued by the Institutional Animal Care and Committee of
NIID.
Human umbilical cord blood was donated by the Tokyo
Cord Blood Bank (Tokyo, Japan) after obtaining informed
consent. The use of human umbilical cord blood cells was
approved by the Institutional Ethical Committees of NIID and
the Tokyo Cord Blood Bank. Human HSCs were isolated using
the CD133 MicroBeads Kit (Miltenyi Biotec, Bergisch Gladbach,
Germany). The purity was approximately 90% as assessed by ﬂow
cytometry.
PREPARATION AND INFECTION OF MV
Recombinant wild-type MV (IC323: AB016162) expressing EGFP
(IC323-EGFP; Hashimoto et al., 2002) and a recombinant vaccine
strain of MV (AIK-C: S58435) expressing EGFP (AIK-C-EGFP;
Fujino et al., 2007) were grown in Vero/hSLAM cells. Virus titers
were determined by plaque assay using Vero/hSLAM cells.
Jurkat/hSLAM cells were infected with various doses of MV
[multiplicity of infection (MOI) = 0.25, 0.05, and 0.01] by incu-
bation at 37◦C for 1 h, washed twice with phosphate buffered
saline (PBS), and seeded on 24-well plates. Cells were harvested
immediately after washing (time 0) or 6, 12, 18, or 24 h later. The
harvested cells were either lysed for RNA extraction or analyzed
by ﬂow cytometry.
Humanized NOD/SCID/JAK3null mice were challenged intra-
venously (i.v.) with different doses [200, 2,000, 10,000, or 20,000
plaque-formingunits (pfu)] of AIK-C-EGFP. Peripheral bloodwas
obtained from MV-infected hNOJ mice at 3, 5, 7, 10, 14, and
21 days post-infection (p.i.). In some experiments, MV-infected
hNOJ mice were sacriﬁced at day 7 p.i. At the time of sacri-
ﬁce, peripheral blood, BM, spleen, and mesenteric lymph nodes
(MLNs) were harvested, and red blood cells were lysed in ACK
buffer (0.15 M NH4Cl, 1 mM KHCO3, and 0.1 mM EDTA-2Na;
pH 7.2–7.4).
FLOW-CYTOMETRIC ANALYSIS OF MV-INFECTED CELLS
PE-conjugated anti-human CD150 (A12) and Paciﬁc Blue-
conjugated anti-hCD45 (HI30) monoclonal antibodies (mAbs)
were purchased from BioLegend Inc. (San Diego, CA, USA).
Cells were stained with these mAbs, ﬁxed with 2% formalin/PBS
for 15 min at room temperature, washed, and kept at 4◦C
prior to ﬂow-cytometric analysis. Dead cells were stained with
a LIVE/DEAD Fixable Dead Cell Stain Kit (L34957; Invitrogen).
Data were collected using a FACScanto (BD Biosciences, San Jose,
CA, USA) and analyzed using the FACSDiva (BD Biosciences) or
FlowJo (Tree Star, San Carlos, CA, USA) software.
STATISTICAL ANALYSIS
Non-parametric one-way ANOVA was performed to compare cell
type-speciﬁcdifferences inhCD45andRNasePmRNAexpression.
Spearman’s rank correlation coefﬁcient test was also performed
to compare the level of MV-N expression and frequency of MV-
infected cells. Prism ver.5 software (GraphPad Software, San
Diego, CA,USA)was used for all analyses. P< 0.05was considered
statistically signiﬁcant.
RESULTS
HUMAN-SPECIFIC qRT-PCR SYSTEM FOR THE DETECTION OF MV
INFECTION
For the detection of MV infection in clinical specimens,
Hummel et al. (2006) established a sensitive qRT-PCR system that
used primer and probe sets targeting the MV-N gene. In our
humanized mouse model, it is necessary to analyze endogenous
mRNA expression in human PBMCs to determine the level of
human cell-associated MV infection in mouse blood. We initially
assumed that hCD45 expression would be suitable to discriminate
human hematopoietic cells from co-existingmouse hematopoietic
cells in vivo. On that basis, we designed human-speciﬁc primer
and TaqMan probe sets for hCD45 and compared their useful-
ness with a primer/probe set for a widely used housekeeping gene,
RNase P. RNAwas extracted fromhumanized (hu-mouse) or non-
humanized (non-hu-mouse) murine splenocytes, and the level of
mRNA was measured by one-step qRT-PCR. Both hCD45 and
RNase P primer/probe sets detected mRNA expression of target
genes from human PBMCs present in hu-mouse spleen, at similar
sensitivities, but neither set detected expression in non-hu-mouse
(Figure 1A). Thus, both primer/probe sets are human-speciﬁc.
Next, we enriched CD14+ monocytes and T cells from PBMCs by
positive and negative magnetic-bead selection, respectively, and
then determined the copy numbers of hCD45 and RNase P in
these cell fractions from each of ﬁve donors. In Figure 1B, the
expression levels of hCD45 (left panel) and RNase P (right panel)
in monocytes and T cells are depicted relative to the level in each
donor’s PBMCs. Because RNase P expression was less affected
by cell type than CD45 expression (*P < 0.05), in subsequent
experiments we exclusively used RNase P primer/probe sets as an
endogenous control for mRNA expression.
PARALLEL INCREASE IN THE TIME COURSE OF MV-INFECTED CELL
FREQUENCY AND MV-N RNA LEVEL IN VITRO
Because wild-type MV mainly utilizes SLAM as the receptor for
entry into lymphoid cells (Tatsuo et al., 2000), the kinetics of MV
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FIGURE 1 | Selection of an endogenous control for the analysis of
MV-infected human PBMCs. (A) RNA was extracted from spleen cells of
hNOJ and non-humanized NOJ, and one-step qRT-PCR was performed
using primer and probe sets designed against the human-speciﬁc hCD45
and RNaseP mRNAs. To calculate copy numbers of these genes, the PCR
products of human CD45 and RNase P were subcloned into plasmids and
used as standard DNAs. (B) Human PBMCs from ﬁve donors were
fractionated into CD14+ monocytes and T cells. RNA from these cell
populations was extracted, and the expression levels of hCD45 and
RNase P were analyzed by qRT-PCR. The graph depicts the expression
levels in these fractionated cells relative to the levels in PBMCs (deﬁned
as 1). Statistical differences in hCD45 and RNase P expression among
these cell populations were evaluated by non-parametric one-way ANOVA
test (*P<0.05).
infection in Jurkat/hSLAM cells can be clearly visualized by ﬂow
cytometry. We infected Jurkat/hSLAM cells with a wild-type MV
encoding EGFP (IC323-EGFP) at MOI of 0.01, 0.05, and 0.25.
Cells were washed and harvested at 6, 12, 18, or 24 h after MV
infection. A subset of the cells in each sample was analyzed by
ﬂow cytometry, and the remainder of the sample was used for
RNA extraction. The mRNA levels of MV-N and RNase P were
determined by qRT-PCR, and the level of MV-N mRNA rela-
tive to RNase P RNA was calculated. Representative results of
three experiments are shown in Figure 2A (ﬂow cytometry) and
Figure 2B (qRT-PCR). Because of the rapid and strong cyto-
pathic effect by MV at the highest MOI (0.25), we omitted the
ﬂow cytometry data corresponding to that condition. At MOI
0.01, a similar frequency of GFP+ cells was detectable at 12 and
18 h p.i., whereas at MOI 0.05, the GFP+ cell frequency was
already high at 12 h p.i. Note that the level of hSLAM was not
down-modulated by MV infection. Over the time course, rela-
tive MV-N expression level at all three MOIs increased in parallel
over two orders of magnitude, indicating that these two meth-
ods yield comparable results (as shown in Figure 2C) and are
useful for monitoring the replication kinetics of MV infection in
vitro.
PARALLEL INCREASE OF MV-INFECTED CELL FREQUENCY AND MV-N
RNA LEVELS IN VIVO
We then applied these detection systems in vivo in MV-infected
hNOJ mice. hNOJ mice were infected with an MV vaccine strain
expressing EGFP (AIK-C-EGFP) at 2000 pfu, and the animals
were sacriﬁced 7 days later. Blood PBMCs and BM cells were
washed with PBS, and a subset of the cells in each sample were
stained with anti-hCD45 mAb. Representative results of ﬂow-
cytometric analysis of BM cells from three mice are shown in
Figure 3A. The percentages of GFP+ cells in mice 127-1, 127-4,
and 127-5 mice were low (0.002%), high (0.35%), and inter-
mediate (0.028%), respectively. The number of human PBMCs
obtained frommouse blood was not sufﬁcient to determine GFP+
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FIGURE 2 |Time course of MV infection in vitro. Jurkat/hSLAM
cells were infected with wild-type MV IC323-EGFP at MOI of 0.01,
0.05, and 0.25, washed, and harvested at the indicated time points.
(A) Cells were stained with PE-conjugated anti-hSLAM mAb, ﬁxed
with 2% formalin/PBS, and GFP expression was analyzed. (B) RNA
was extracted from cells, and expression levels of MV-N and RNase
P were analyzed by one-step qRT-PCR. The copy numbers of MV-N
and RNase P were determined, and the ratio of MV-N copies to
RNase P copies is depicted on the vertical axis. (C) Correlation
between the percentage of GFP+ Jurkat/SLAM cells and the time
course of MV-N expression. Spearman’s rank correlation coefﬁcient
was used for statistical analysis.
cell frequencies by ﬂow cytometry. Next, we extracted RNA from
PBMCs and BMcells and analyzedMV-N expression by qRT-PCR,
as described in the previous section. MV-N expression paral-
leled the GFP+ frequencies in BM (Figure 3B). Notably, a high
level of MV-N expression was also detected in PBMCs of mouse
127-4, suggesting that the level of MV-N expression per single
hematopoietic cell is similar between blood and BM. We plotted
the GFP+ frequency and MV-N expression level in BM cells of
eight mice. As shown in Figure 3C, these values were well corre-
lated (R = 0.9286). Taken together, these data indicate that MV
infection in vivo is detectable in BM by both ﬂow cytometry and
MV-N RNA qRT-PCR analysis, but only MV-N RNA qRT-PCR is
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FIGURE 3 | Analysis of MV infection in vivo. Three hNOJ mice (127-1, -4,
and -5) were infected intravenously with 2,000 pfu of the MV vaccine
strain, AIK-C-EGFP. Mice were sacriﬁced at day 7 post-infection, and blood
and bone marrow cells (BM) were obtained. (A) BM cells were stained
with PB-anti-human CD45 mAb, ﬁxed with 2% formalin/PBS, and GFP
expression was analyzed. (B) PBMCs from blood and BM cells were lysed,
and RNA was prepared. The expression MV-N and RNase P was analyzed
as described in the legend for Figure 2B. (C) Correlation between the
percentage of GFP+ cells among hCD45+ cells in BM and the level of
MV-N expression in MV-infected hNOJ mice, at day 7 (n = 4) or day 10
(n = 4) p.i. Spearman’s rank correlation coefﬁcient was used for statistical
analysis.
sensitive enough to detect PBMC-associated MV infection in the
blood.
KINETICS OF MV GROWTH CAN BE MONITORED IN THE BLOOD OF
hNOJ MOUSE
Finally, we measured MV growth kinetics in vivo by
qRT-PCR analysis using sequential blood samples obtained from
MV-infected hNOJmice; it was not feasible to perform these mea-
surements by ﬂow cytometry because of the paucity of human
PBMCs in the blood. Two or three hNOJ mice in each group were
infected intravenously with 200, 2000, or 20,000 pfu AIK-C-EGFP
and followed up to 21 days p.i. The level of PBMC-associated MV
RNA in individual mice is shown in Figure 4A. We noticed two
peaks of MV replication, the ﬁrst at around day 3 p.i., and the sec-
ond at day 10 p.i., irrespective of the initial inoculum. Two mice
infected with 20,000 pfu MV exhibited a high level of MV replica-
tion that peaked at day 10 p.i. One mouse infected with 2,000 pfu
exhibited a high level of MV replication at day 3 p.i., followed by
a small peak at day 10 p.i. For some mice, we counted the number
of human cells per 50 μl of blood used for RNA extraction. The
data are shown in Figure 4B. We were able to detect high levels
of MV in samples containing less than 2,000 cells, indicating that
the qRT-PCR system is sensitive enough to detect low numbers of
MV-infected human cells.
Although MV replication was not obvious in three mice
infected with the smallest dose (200 pfu), one of these animals
exhibited an increase inMVRNAexpression at day 21p.i. (gray cir-
cle). We sacriﬁced this particular mouse and used ﬂow cytometry
to analyze GFP expression in its blood, spleen, MLN, and BM. As
shown in Figure 4C, GFP+ cells were present in spleen (0.308%)
and all the other tissues, albeit at a lower frequency, indicating that
MV infection can occur even at a low dose (200 pfu) and spread
slowly in the systemic lymphoid tissues of hNOJ.
Itmay be necessary to acquire at least 30,000 events to be sure of
having>10,000 cells for ﬂow cytometry analysis. This is because of
the substantial amount of sample loss that occurs in this system.
The ﬂow cytometry data presented in Figure 4C were obtained
by analyzing ∼0.4 ml blood from a sacriﬁced mouse. However,
even under these conditions, the proportion of MV-infected cells
detected was only 0.056%; indeed, the cells are barely visible on
the plot. Therefore, it appears that ﬂow cytometry is not a suitable
method for the sequential monitoring of infected (GFP+) cells.
Thus, the qRT-PCR system we have developed here allowed us to
monitor systemic MV replication using a small volume of blood
from humanized mice.
DISCUSSION
Based on a highly sensitive MV-N RNA detection method pre-
viously developed by Hummel et al. (2006), which could detect
one copy of synthetic MV RNA/reaction, we developed a novel
one-step real-time qRT-PCR system for the purpose of monitor-
ing MV replication in the blood of MV-infected humanized mice.
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FIGURE 4 | Monitoring of MV replication in vivo. Two to three hNOJ
mice per group were challenged with MV AIK-C-EGFP at 20,000 (squares),
2,000 (triangles), or 200 pfu (circles). The PBMCs of these mice were
collected at day 3, 5, 7, 10, 14, and 21 p.i. (A)The level of MV-N expression
in the blood of infected hNOJ. Vertical axis shows the level of MV-N relative
to that of RNaseP, as described in the legend for Figure 2B.(B) For some
mice (depicted using the same symbol as (A)), the number of human cells
per 50 μl of blood used for RNA extraction and analyzed for MV-N
expression was plotted on the X-axis. (C) An hNOJ mouse infected with
MV at a low dose (gray closed circle, 200-2) exhibited an increased level of
MV-N. At day 21 p.i., the mouse was sacriﬁced; cells from blood, spleen,
BM, and mesenteric lymph node (MLN) were prepared. Cells were stained
and analyzed as described in the legend for Figure 2A.
Because MV replication usually occurs in association with cells
(Grifﬁn, 2007), it is necessary to evaluate the endogenous RNA
expression level of human PBMCs that co-exist with mouse blood
cells. To this end, we designed human-speciﬁc primer/probe sets
for the CD45 and RNase P mRNAs. When we analyzed the detec-
tion efﬁciencies of these two primer/probe sets using distinct cell
types present in humanPBMCs,we found that RNase P expression
was less dependent than CD45 expression on cell type. Using this
qRT-PCR system with RNase P as an internal control, we can
reliably detect MV replication with high sensitivity in humanized
mice in vivo. When MV expressing GFP was used for infections
in vitro or in vivo, the level of MV-N RNA was closely correlated
with the frequencies of GFP+ MV-infected cells determined by
ﬂow cytometry.
Our qRT-PCR system allowed us to follow MV replication in
vivo using a small amount of blood, with no need to sacriﬁce
mice at each time point. Although ﬂow-cytometric analysis pro-
vides valuable information, such as the proportions of various cell
types and the surface phenotypes of MV-infected cells, the small
number of human cells circulating in the mouse blood may not
be sufﬁcient for precise estimation of MV-infected cells by ﬂow
cytometry. By contrast, our qRT-PCR system was able to detect
MV-N RNA in fewer than 2,000 human PBMCs (Figure 4B).
This is an important technological advantage considering that
individual humanized mice exhibit variable levels of human cell
engraftment, i.e., chimerism (Terahara et al., 2013); moreover,
there may exist donor-to-donor variation in susceptibility to MV
infection. Thus, it should be possible to select humanized mice
with a degree of MV infection appropriate for the purpose of a
given experiment.
In this study, MV was inoculated through the tail vein, and
infected cells were distributed to systemic lymphoid tissues as well
as BMs, where human hematopoietic cells localize in humanized
mice (Traggiai et al., 2004). MV may also be distributed to other
organs, such as lung and intestinal tissue, as demonstrated in the
case of HIV infection using the BLT mouse (Sun et al., 2007). To
our surprise, by monitoring MV replication in PBMCs of human-
ized mice, we noticed two peaks of MV replication, at around 3
and 10 days p.i., in some mice. This pattern of MV replication did
not depend on the initial dose of MV inoculum. We do not know
why MV replication showed two peaks in many animals. How-
ever, it was recently reported in a monkey model that MV RNA
persists in PBMCs for more than 1 month after primary infection,
and declined in three phases (Lin et al., 2012). The authors of that
study hypothesized that both T cells, including regulatory T cells
(Treg), and antibody responses contributed to the dynamics of
MV replication in vivo. Although hNOJmice are reported to show
poor immune responses, the role of regulatory T cells should be
considered. This is because these cells regulate HIV-1 infection
in humanized mice (Jiang et al., 2008). Alternatively, it may be
that the intravenous injection of MV rapidly kills the target cells
(probably those showing an activated phenotype) within 3 days.
The low number of MV-infected cells then gradually transmits the
virus to the human cells that are replenished from the BM stem
cell pool. Further investigations are required to clarify this issue.
The humanized mouse model is expected to be a useful tool
for studying virus infection (Akkina, 2013). Although the human
immune system is not fully reconstructed by the transplantation
of human HSCs alone, we believe that further improvements are
possible,whichwill allowus to utilize thismousemodel to not only
evaluate vaccine and drug efﬁcacy but also to increase our under-
standing of the pathogenesis of MV infection. The described novel
method of monitoring MV-infected human cells in the blood will
www.frontiersin.org October 2013 | Volume 4 | Article 298 | 7
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be useful for studying MV-based vaccines in humanized mouse
models without the need to sacriﬁce the mice.
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